Coherus BioSciences Announces CEO Change and Board Refresh
Ticker: CHRS · Form: 8-K · Filed: Dec 4, 2024 · CIK: 1512762
Sentiment: neutral
Topics: management-change, board-composition
TL;DR
CEO Dennis Lanfear OUT, Paul Reider IN. Board shakeup too.
AI Summary
On November 27, 2024, Coherus BioSciences, Inc. announced changes in its executive team and board of directors. Specifically, Dennis M. Lanfear has stepped down as Chief Executive Officer and will be succeeded by Paul W. Reider. Additionally, several directors have departed, and new directors have been appointed.
Why It Matters
This filing indicates a significant leadership transition at Coherus BioSciences, which could impact the company's strategic direction and operational execution.
Risk Assessment
Risk Level: medium — Leadership changes and board refreshes can signal strategic shifts or internal challenges, introducing uncertainty.
Key Numbers
- 001-36721 — SEC File Number (Identifier for Coherus BioSciences, Inc.)
Key Players & Entities
- Coherus BioSciences, Inc. (company) — Registrant
- Dennis M. Lanfear (person) — Outgoing CEO
- Paul W. Reider (person) — Incoming CEO
- November 27, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
FAQ
Who is the new CEO of Coherus BioSciences, Inc.?
Paul W. Reider has been appointed as the new Chief Executive Officer.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 27, 2024.
What was Dennis M. Lanfear's role prior to this filing?
Dennis M. Lanfear was the Chief Executive Officer of Coherus BioSciences, Inc.
What is the principal executive office address for Coherus BioSciences, Inc.?
The address is 333 Twin Dolphin Drive, Suite 600, Redwood City, CA 94065.
What is the SIC code for Coherus BioSciences, Inc.?
The SIC code is 2836, for BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES).
Filing Stats: 449 words · 2 min read · ~1 pages · Grade level 12.3 · Accepted 2024-12-04 16:29:24
Key Financial Figures
- $0.0001 — ge on which registered Common Stock, $0.0001 par value per share CHRS The Nasdaq
Filing Documents
- chrs-20241127x8k.htm (8-K) — 34KB
- 0001558370-24-016012.txt ( ) — 186KB
- chrs-20241127.xsd (EX-101.SCH) — 4KB
- chrs-20241127_def.xml (EX-101.DEF) — 3KB
- chrs-20241127_lab.xml (EX-101.LAB) — 12KB
- chrs-20241127_pre.xml (EX-101.PRE) — 11KB
- chrs-20241127x8k_htm.xml (XML) — 5KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: December 4, 2024 COHERUS BIOSCIENCES, INC. By: /s/ Dennis M. Lanfear Name: Dennis M. Lanfear Title: Chief Executive Officer